U.S. National Institutes Of Health, India's Cadila Healthcare Join Forces To Develop A New HPV Vaccine
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - India's Zydus Cadila has joined hands with the U.S.-based National Institutes of Health to develop a new prophylactic vaccine against human papilloma virus - known to be a major cause of cervical cancer